Showing results (101-110 of 113) with videos related to
Sort By:
Pageof 12
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 28, 2017
Alectinib for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401)Eiji Iwama, Yasushi Goto, Haruyasu Murakami, et al.Annals of Surgery|June 3, 2020
RAD51 Expression as a Biomarker to Predict Efficacy of Preoperative Therapy and Survival for Esophageal Squamous Cell Carcinoma: A Large-cohort Observational Study (KSCC1307)Hiroshi Saeki, Tomoko Jogo, Tetsuro Kawazoe, et al.BMC Pulmonary Medicine|November 7, 2024
Update of prognosis and characteristics of chronic obstructive pulmonary disease in a real-world setting: a 5-year follow-up analysis of a multi-institutional registryTomotsugu Takano, Kazuya Tsubouchi, Naoki Hamada, et al.Scientific Reports|November 5, 2025
Diagnostic utility of high-mobility group box 1 for acute exacerbations of idiopathic pulmonary fibrosisNaoki Hamada, Shoji Tokunaga, Toyoshi Yanagihara, et al.BMJ Open Respiratory Research|November 14, 2023
Survival and acute exacerbation for patients with idiopathic pulmonary fibrosis (IPF) or non-IPF idiopathic interstitial pneumonias: 5-year follow-up analysis of a prospective multi-institutional patient registryKazuya Tsubouchi, Naoki Hamada, Shoji Tokunaga, et al.Journal of Bone and Mineral Metabolism|October 14, 2017
Characteristics of patients with fragility hip fractures in the northern Kyushu district in Japan: a multicenter prospective registry based on an electronic data capture systemAkiko Oyamada, Yoshihiro Matsumoto, Yoshifumi Wakata, et al.Cancer Science|September 24, 2025
GWAS Identifies SNPs Associated With Severe Adverse Events and Efficacy in Advanced Renal Cell Carcinoma Treated With NivolumabTokiyoshi Tanegashima, Masaki Shiota, Shusuke Akamatsu, et al.Cancer Immunology, Immunotherapy : CII|February 2, 2023
Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trialMasaki Shiota, Hideaki Miyake, Masayuki Takahashi, et al.International Journal of Urology : Official Journal of the Japanese Urological Association|August 2, 2023
Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC studyLeandro Blas, Masaki Shiota, Hideaki Miyake, et al.Journal of Orthopaedic Surgery (Hong Kong)|August 31, 2019
Predictive factors of mortality of patients with fragility hip fractures at 1 year after discharge: A multicenter, retrospective study in the northern Kyushu district of JapanAtsushi Kimura, Yoshihiro Matsumoto, Yoshifumi Wakata, et al.Pageof 12